ML604086

ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca 2+ concentrations In Vitro ML604086 (0-100 µM) inhibits CCL1 mediated chemotaxis and increases in intracellular Ca 2+ concentrations of cell lines stably expressing cyno CCR8 with IC 50 s of 1.3 µM and 1.0 µM, respectively. ML604086 (10, 30 µM; 64 h) inhibits CCL1 binding to CCR8 on CD4 T-cells, and inhibits the serotonin receptor 5HT1a with the inhibition rate of 30%, 70% at 10, 30 µM respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ML604086 (1.038 mg/kg; intravenous infusion) shows no effect on airway eosinophilia, pro-inflammatory cytokine production or airway resistance and compliance in Macaca fascicularis . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 3.0-5.0 kg male and female adult Macaca fascicularis (primate model of asthma)Dosage: 1.038 mg/kg Administration: Intravenous infusion Result: Did not effected the Changes in airway resistance and compliance induced by allergen provocation and increasing concentrations of methacholine. IC50& Target:CCR8

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet